Sandoz Group AG Stock

Equities

SDZ

CH1243598427

Pharmaceuticals

Real-time Estimate Cboe Europe 08:25:42 2024-05-08 EDT 5-day change 1st Jan Change
31.45 CHF +4.07% Intraday chart for Sandoz Group AG +1.48% +16.26%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 10.29B 9.35B 14.16B Sales 2025 * 10.95B 9.95B 15.06B Capitalization 14.32B 13.02B 19.7B
Net income 2024 * 719M 654M 989M Net income 2025 * 989M 899M 1.36B EV / Sales 2024 * 1.65 x
Net Debt 2024 * 2.65B 2.41B 3.65B Net Debt 2025 * 2.81B 2.55B 3.86B EV / Sales 2025 * 1.57 x
P/E ratio 2024 *
19.3 x
P/E ratio 2025 *
14.5 x
Employees 22,633
Yield 2024 *
1.91%
Yield 2025 *
2.46%
Free-Float 91.55%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.04%
1 week+1.48%
Current month+1.00%
1 month+21.70%
3 months+12.24%
6 months+30.65%
Current year+16.26%
More quotes
1 week
30.06
Extreme 30.06
31.86
1 month
25.33
Extreme 25.33
31.86
Current year
25.33
Extreme 25.33
31.86
1 year
22.70
Extreme 22.7
31.86
3 years
22.70
Extreme 22.7
31.86
5 years
22.70
Extreme 22.7
31.86
10 years
22.70
Extreme 22.7
31.86
More quotes
Date Price Change Volume
24-05-08 31.48 +4.17% 757 882
24-05-07 30.22 -2.52% 1,653,892
24-05-06 31 0.00% 782,708
24-05-03 31 0.00% 1,137,781
24-05-02 31 -0.48% 1,209,578

Delayed Quote Swiss Exchange, May 08, 2024 at 08:10 am

More quotes
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
33.32 USD
Average target price
38.55 USD
Spread / Average Target
+15.70%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW